In the early stage of antibody drug development, it is an urgent need to screen out effective molecules from a candidate library, which highlighting the role of in vitro bioassay in the development of antibody drugs. Traditional biological activity testing depends on primary immune cells, which is laborious with poor reproducibility, limiting its usage for high throughput screening. GenScript ProBio could help customize the construction of functional reporter assay according to customers’ needs, and provide a quantitative bioassay method with robust consistency and high accuracy. The established reporter cell-based assay is reliable for high throughput antibody screening, biological activity determination, stability determination, QC lot release, etc., providing a stable and cost-economic choice for accelerating antibody drug development.
The functional reporter assays by GenScript ProBio are a reliable, sensitive and simplified detection system based on the firefly luciferase. Briefly, the system relies on the interaction of the ligand and its receptor, thus activating the specific signaling pathway, followed by a transcription factor binding to the response element(RE) and induction of reporter gene luciferase expression. The bioluminescence signal of luciferase is measured and used to reflect the difference in efficacy of candidates. Dual luciferase reporter cell lines, β-galactosidase, SEAP, GFP and other reporter gene cell lines are also available according to customers’ needs.
Contact us for more information about our Reporter Gene Assay Cell Line development services.
The response window is an important indicator for reporter gene assay cell line . Rich experience in RE sequence optimization assists us to develop a customized assay with high sensitivity.
GenScript ProBio will scrutinize the key factors such as cell seeding density, serum concentration, and incubation conditions to achieve an optimal assay.
Two engineered cell lines - PD-L1/CD155 aAPC/CHO-K1 Cell and PD-1/TIGIT Effector Cell are used in this bioassay. The interaction between TIGIT and CD155, and PD-1 and PD-L1 inhibits TCR-mediated activation. When disrupting the interactions of both pairs, TCR activation will be restored indicated by the luminescence signal.